News for Genetron Holdings Limited (GTH)

Worldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 29% p.a., Reaching $10.1B by 2029 “ Market Report by DeciBio Consulting LLC

Genetron Health Announces Completion of Going Private Transaction

BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology...

BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology...

BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology...

Genetron Holdings is a Buy with a 9.2% arbitrage return and favorable odds of timely deal closure. Read more to see our analysis on GTH stock.

The cancer-screening products maker is in danger of being forcibly delisted due to its sinking stock price.

Key Takeaways: Burning Rock announced its shares could be delisted due to prolonged trading below the required $1 threshold The cancer detection specialist’s former biggest revenue source tumbled 40.6% in the third quarter amid an industry crackdown, spotlighting a major risk for Chinese companies By Doug Young

Discover lucrative investment opportunities in merger arbitrage with wide spreads ranging from 10% to 137%.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN...

BALA CYNWYD, Pa., Oct. 23, 2023 (GLOBE NEWSWIRE) --  Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to...

BALA CYNWYD, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to...

By technology, the LDCT segment will account maximum share in lung cancer screening market during 2022-2030. The lung cancer screening industry majorly...

Key Takeaways: Burning Rock’s net loss narrowed 29% to 185 million yuan in the first quarter from the same period a year earlier, helped by lower R&D and sales expenses Revenues from R&D services for drug companies more than doubled, becoming the company’s latest growth engine By Molly Wen

Burning Rock’s net loss narrowed 29% to 185 million yuan in the first quarter from the same period a year earlier, helped by lower R&D and sales expenses.

Read Head-To-Head Comparison: Genetron (NASDAQ:GTH) & PotNetwork (OTCMKTS:POTN) at ETF Daily News

Read Contrasting Aeon Global Health (OTCMKTS:AGHC) & Genetron (NASDAQ:GTH) at ETF Daily News

First Choice Healthcare Solutions (OTCMKTS:FCHS) and Genetron (NASDAQ:GTH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability. Institutional and Insider Ownership 0.6% of First Choice Healthcare Solutions shares are held by […]